Program
LTI-03
Also written as “Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rein Therapeutics | 21 open or running | phase 2since Apr 28, 2025 | May 20, 2022 | Sep 30, 2027phase 2 · NCT06968845 |
| Lung Therapeutics | 10 open or running | phase 1since Jan 12, 2020 | Jan 12, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 12, 2020First study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Lung TherapeuticsLung Therapeutics · NCT04233814 · 71 enrolled · United Kingdom
- May 20, 2022Rein Therapeutics's first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Rein TherapeuticsRein Therapeutics · NCT05954988 · 24 enrolled · United States, Germany, United Kingdom
- Apr 28, 2025Phase 2 study in Idiopathic Pulmonary FibrosisRein Therapeutics · NCT06968845 · 120 planned · United States, Australia, Bulgaria and more
Ahead
- Sep 30, 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisRein Therapeutics · NCT06968845
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06968845Idiopathic Pulmonary Fibrosis · United States, Australia, Bulgaria and more | 2 | Recruiting | Rein Therapeutics | Sep 30, 2027 | 120 |
| NCT05954988Idiopathic Pulmonary Fibrosis · United States, Germany, United Kingdom | 1 | Completed | Rein Therapeutics | Sep 25, 2024 | 24 |
| NCT04233814Idiopathic Pulmonary Fibrosis · United Kingdom | 1 | Completed | Lung Therapeutics | Dec 23, 2021 | 71 |
How it is read
Names in the registry
- “LTI-03”, 2 entries
- “Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.